

## BRIEF REPORT

# Evaluation of Safety Measures at a Medical Summer Camp During the SARS-CoV-2 Pandemic

Kristy Wilkinson, MD<sup>1</sup>; Ashar Ata, MBBS, PhD<sup>2</sup>; Stephanie Neaton, RN<sup>3</sup>; Christopher Woll, MD<sup>3,4</sup>

<sup>1</sup>Department of Pediatrics, Albany Medical Center, Albany, NY; <sup>2</sup>Departments of Surgery and Emergency Medicine, Albany Medical Center, Albany, NY; <sup>3</sup>Double H Hole-in-the-Woods Ranch, Lake Luzerne, NY; <sup>4</sup>Departments of Pediatrics and Emergency Medicine, Albany Medical Center, Albany, NY

**Introduction**—SARS-CoV-2 poses challenges for the safe delivery of a camp experience with a medically complex camper population. Multiple studies have investigated the effect of nonpharmaceutical interventions for preventing SARS-CoV-2 transmission in traditional summer camp settings, but none in the medical summer camp settings. Our objective was to describe and evaluate the nonpharmaceutical interventions on SARS-CoV-2 transmission rate in a medical summer camp setting.

**Methods**—This was a single-institution cross-sectional study conducted between June 2021 and August 2021 in a rural summer camp setting in upstate New York. Nonpharmaceutical interventions consisted of prearrival guidance on low-risk activities, obtaining negative SARS-CoV-2 polymerase chain reaction results within 72 h prior to arrival, adult SARS-CoV-2 vaccine mandate, universal masking mandate, small cohorts, daily symptom screening, and rapid testing on site. Primary cases were defined as an individual with a positive SARS-CoV-2 test result of any type while at camp or 2 wk after departure from camp without any known exposure at camp; secondary cases were defined as cases from potential exposures within camp.

**Results**—Two hundred and ninety-three campers were included. Nine individuals were tested owing to potentially infectious symptoms while at camp. Thirty-four campers were tested because they arrived from a county with an a priori intermediate level of SARS-CoV-2 community spread. Zero on-site rapid tests were positive for SARS-CoV-2.

**Conclusions**—We describe the implementation of multilayered nonpharmaceutical interventions at a medical summer camp during the SARS-CoV-2 pandemic.

**Keywords:** COVID-19, medical summer camp, nonpharmaceutical interventions, risk mitigation, public health

## Introduction

Advances in medical diagnostics and therapeutics have resulted in more children living with chronic medical conditions.<sup>1</sup> While mortality for these individuals has decreased, psychosocial morbidity, such as anxiety, depression, and self-esteem disturbances, has increased.<sup>2</sup> SARS-CoV-2, the microbe responsible for COVID-19,

has had significant ramifications for the lives of children since 2019.<sup>3</sup> Children have been exposed to loss of loved ones, household financial hardship, food insecurity, asynchronous education, restrictions of in-person interactions, and gaps in typical psychosocial outlets, resulting in negative health outcomes.<sup>4-7</sup> Summer camps foster the development of social skills, team work, problem solving, and self-identity.<sup>8,9</sup> Medically complex children often cannot participate in traditional summer camps and therefore are not provided the opportunity to develop such skills. Medically complex children do, however, have the opportunity to attend medical summer camps, where they learn the same life-long skills as in a traditional summer camp, in addition to learning different coping mechanisms, management of their own illness, and altruism.<sup>10-14</sup> Therefore, the pandemic has

Corresponding author: Christopher Woll, MD, Departments of Pediatrics and Emergency Medicine, Albany Medical Center, Albany, NY; e-mail: [wollc@amc.edu](mailto:wollc@amc.edu).

Submitted for publication August 2022.

Accepted for publication October 2022.

© 2022 Wilderness Medical Society. Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.wem.2022.10.006>

the potential for greater negative biopsychosocial ramifications in the medically complex child.<sup>11,15,16</sup>

Multiple studies have described the range of non-pharmaceutical interventions (NPIs) implemented in traditional summer camp settings. These NPIs have been used to mitigate the transmission of SARS-CoV-2 with varying degrees of success.<sup>17-22</sup> To our knowledge, none of these studies has evaluated the role of NPIs in a medical summer camp setting. The objective of this study was to describe the demographics, NPIs, and transmission patterns of SARS-CoV-2 among medically complex children while attending a medical summer camp.

## Methods

### STUDY DESIGN

This was a single-institution cross-sectional study conducted between June 2021 and August 2021 in a rural summer camp setting in upstate New York. The study was conducted at a residential medical summer camp with approximately 50 to 60 campers per session with 6 sessions of 5 d duration. The study was determined to be exempt from review by the Albany Medical Center institutional review board, and therefore consent was not required. All enrolled campers were included. No one was excluded from the study. Data were entered directly into a Research Electronic Data Capture (REDCap) tool hosted at Albany Medical Center. Individual-level demographic data (ie, age, gender, and county of residence) and medical data (ie, medical history, SARS-CoV-2 vaccination status, and SARS-CoV-2 infection history) were gathered from the self-reported application. All “prearrival” SARS-CoV-2 polymerase chain reaction (PCR) tests and “during session” SARS-CoV-2 nucleic acid amplification tests (NAATs) and their results were gathered on an encrypted central camp database.

### NPIS

#### *Prearrival Screening*

Seventy-two hours prior to the first day of a camp session, the medical team assessed the level of SARS-CoV-2 transmission within the 11 counties surrounding the camp. An a priori definition of risk included low risk, intermediate risk, and high risk (Figure 1).

If community risk was low, prearrival and in-session mitigation strategies were implemented as described later. If community risk was intermediate, the same mitigation steps as for low risk were implemented in addition to performing rapid SARS-CoV-2 NAATs upon arrival to the camp for all individuals coming from counties with

#### **Low:**

7 d average <10 cases/100K AND <5% positivity rate

#### **Intermediate:**

7 d average 10-25 cases/100K OR 5-8% positivity rate

#### **High:**

7 d average >25 cases/100K AND >8% positivity rate

**Figure 1.** Prearrival risk stratification of SARS-CoV-2 infection community spread.

non-low-risk community infectivity. If community risk was high, the camp did not open for that session.

#### *Mitigation Steps*

Prearrival mitigation steps included a prearrival screening telephone call and prearrival SARS-CoV-2 testing. Screening telephone calls were performed by the medical staff calling the camper’s family 2 wk prior to arrival to evaluate travel/exposure history. The medical staff also informed the family that the household should quarantine until arrival at the camp. Prearrival testing involved all campers providing documentation of a negative SARS-CoV-2 PCR result within 72 h prior to arrival on site.

#### *In-Session Mitigation Steps*

*Staff vaccination mandate:* All staff and volunteers were required to be fully vaccinated against SARS-CoV-2 2 wk prior to arrival on site.

*Daily symptom screening:* Every morning prior to leaving their cabin, all staff members and campers underwent a standardized symptoms screen by medical staff (pinpoint SARS-CoV-2 screening, Wellcheck, Monkton, MD). If an individual reported any symptoms, they were evaluated by the camp physician.

*Cohorting:* On site, cohorts were made up of 10 campers and 5 to 7 staff members.

*Universal masking:* Masks were worn by all campers/staff unless the only people present were within the on-site cohort or they were eating/drinking, participating in an aquatic activity, or sleeping.

*Intentional staffing pattern:* Activity areas that required specific training/certifications had dedicated staff assigned to that area and were counted within an on-site cohort. This allowed for small cohorts without a lot of “cross-contamination” within a program area by the program staff.

*Intentional common space utilization to allow for social distancing:* Each on-site cohort had a designated indoor and outdoor dining area to physically distance

**Table 1.** Camper demographics

Variable of interest	n (%)
Age (y)	
6	3 (1)
7	10 (4)
8	8 (3)
9	18 (7)
10	31 (13)
11	25 (10)
12	27 (11)
13	28 (12)
14	35 (14)
15	22 (9)
16	35 (14)
Race	
White	166 (66)
African American	52 (21)
Asian	6 (2)
Hispanic-Latino	17 (7)
Other	1 (0.41)
Sex	
Male	118 (49)
Female	122 (50)
Other	2 (0.83)
State of residence:	
California	1 (0.41)
Colorado	1 (0.41)
Connecticut	8 (3)
Delaware	1 (0.41)
Florida	2 (0.83)
Georgia	1 (0.41)
Maryland	1 (0.41)
Massachusetts	9 (3.72)
New Hampshire	5 (2)
New Jersey	14 (6)
New York	168 (69)
North Carolina	3 (1)
Pennsylvania	19 (8)
South Carolina	1 (0.41)
Utah	2 (0.83)
Vermont	6 (2.48)
County of residence	
Saratoga	11 (4)
Albany	23 (10)
Schenectady	15 (6)
Warren	4 (2)
Rensselaer	11 (5)
Fulton	1 (0.41)
Schoharie	1 (0.41)
Washington	1 (0.41)
Other	175 (72)
Vaccinated against COVID-19?	
Yes	87 (36)
Vaccinated 2 wk before arrival at camp <sup>a</sup>	
Yes	72 (83)
Positive COVID-19 test result >72 h before arrival at camp?	
Yes	9 (4)
Pediatric chronic medical conditions	
Yes	192 (79)
Type of chronic medical condition <sup>b</sup>	
Corrected congenital heart disease	1 (0.52)
Uncorrected congenital heart disease	1 (0.52)
Cardiomyopathy/Heart failure	0 (0)
Arrhythmia	1 (0.52)

(continued)

**Table 1 (continued)**

Variable of interest	n (%)
Acquired cardiac disease (myocarditis, Kawasaki, etc)	0 (0)
Other cardiac diseases expected to last $\geq 12$ mo, and that involve $\geq 1$ organ system	0 (0)
Chronic invasive ventilation (tracheostomy)	0 (0)
Chronic noninvasive positive pressure ventilation	0 (0)
Asthma	9 (5)
Chronic lung disease/Bronchopulmonary dysplasia	0 (0)
Cystic fibrosis	0 (0)
Other pulmonary diseases expected to last $\geq 12$ mo	0 (0)
Chronic kidney disease on dialysis	0 (0)
Chronic kidney disease not on dialysis	1 (0.52)
Congenital anomalies of the kidney and urinary tract	3 (1.56)
Other kidney diseases expected to last $\geq 12$ mo	0 (0)
Static encephalopathy/Cerebral palsy	19 (10)
Seizure/Epilepsy	11 (6)
Stroke	1 (0.52)
Developmental delay	7 (4)
Other neurologic diseases expected to last $\geq 12$ mo	30 (16)
Chronic liver disease	1 (0.52)
Inflammatory bowel disease	7 (4)
Other gastrointestinal diseases expected to last $\geq 12$ mo	14 (7)
Immunodeficiency	6 (3)
SLE	1 (0.52)
Diabetes (Type 1 or 2)	1 (0.52)
Leukemia/lymphoma	10 (5)
Sickle cell disease	43 (22)
Hemophilia	12 (6)
Von Willebrand disease	12 (6)
Other hemoglobinopathies	5 (3)
Solid tumor	4 (2)
Other rheumatologic/endocrinologic/hematologic/ oncologic diseases expected to last $> 12$ mo	33 (17)
Muscular dystrophy	9 (5)
Congenital adrenal hyperplasia	3 (2)
Mitochondrial disorder	5 (3)
Other metabolic disorders expected to last $\geq 12$ mo	2 (1)

SLE, systemic lupus erythematosus.

<sup>a</sup>Of those who were vaccinated.<sup>b</sup>Percentage of those with chronic medical conditions. Chronic medical conditions are not mutually exclusive.

every cabin from one another, while all masks were down during mealtime.

*Specific-person under investigation protocols:* Any potentially infectious complaint was evaluated in an infirmary physically separate from the noninfectious infirmary. Any infectious complaint had a rapid SARS-CoV-2 NAAT performed on site. If negative, they could return to camp activities per standard medical policies. If positive, the whole cabin cohort was sent home.

## STATISTICAL ANALYSIS

Descriptive analysis was used to describe camper demographics, index cases, primary cases, secondary cases,

**Table 2.** SARS-CoV-2 transmission patterns.

Variable of interest	n (%)
Positive daily screening for COVID-19 while at camp	0 (0)
Developed COVID-19 symptoms while at camp	4 (2)
Primary case while at camp	0 (0)
Number of close contacts linked to this index case	0 (0)
Number of cases within close contacts linked to this index case	0 (0)
Primary attack rate	0 (0)
Secondary transmission rate	0 (0)

primary attack rate, and secondary attack rate. Index cases were defined as an individual with a positive SARS-CoV-2 test result of any type while at camp or 2 wk after departure from camp without any known exposure at camp; primary cases were defined as cases from potential exposures while at camp. Secondary cases were defined as cases from potential exposures to primary cases. A contact was defined as any individual who had close contact (<2 m [6 ft] for  $\geq 15$  min within a 24 h period) with a primary case with or without masks while at camp. The primary attack rate and secondary transmission rate were calculated according to previous studies.<sup>18</sup> The primary attack rate was calculated as the number of new primary cases during the camp session of infection divided by the number of campers on-site during the session of infection. The secondary transmission rate was calculated as the number of secondary cases among contacts of index cases. Chronic medical conditions were defined as any medical condition expected to last >12 mo and require the care of a specialist provider.

## Results

The study cohort consisted of 499 total individuals, with 242 of those being campers. The mean age of the campers was 12 y. As seen in [Table 1](#), 168 (69%) were from the state of New York, with 27% of those campers being from the Capital District region of New York (composed of Albany, Columbia, Fulton, Greene, Montgomery, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, and Washington counties). Of the 242 campers, 192 (79%) had a chronic medical condition; the most common were sickle cell disease (22%), bleeding/clotting disorders (13%), cerebral palsy (10%), and epilepsy (6%). Of the 242 campers, 87 (36%) were vaccinated. All eligible campers were vaccinated with the Pfizer Biontec messenger RNA vaccine because this was the only SARS-CoV-2 vaccine that had US Food and Drug Administration emergency use approval in patients aged <18 y old at the time of the study. Two hundred

thirty-nine campers (99%) had a negative SARS-CoV-2 PCR test result prior to arrival at camp.

A total of 232 infirmary visits were logged, a combination of staff, volunteers, and campers. As seen in [Table 2](#), 38 total SARS-CoV-2 tests were performed during the study period, with 4 resulting from symptomatic testing and 34 resulting from asymptomatic screening in persons coming from counties with intermediate risk of SARS-CoV-2 transmission. Overall, there were no positive SARS-CoV-2 test results while persons were on site or for 2 wk after their departure from camp. There were no index, primary, or secondary cases of SARS-CoV-2 infection. No sessions were canceled because of high-community spread or SARS-CoV-2 outbreak within camp.

## Discussion

No transmission of SARS-CoV-2 was observed within this residential summer camp for >60 d. This is the first study to our knowledge that evaluates the transmission of SARS-CoV-2 within a residential summer camp for medically complex children. Our findings correspond with those from previous studies that show low-transmission rates when a multilayered mitigation approach to infection control is implemented.<sup>17-22</sup> Similarly, our findings are consistent with findings of studies showing low-transmission rates within schools that have a multilayered mitigation approach to infection control.<sup>23-26</sup> Our findings are contrasted by findings of studies that show high-transmission rates within residential summer camp communities without a multilayered mitigation approach to infection control.<sup>27</sup>

The limitations of our study include a small sample size of 242 campers. This study was limited to only one medical summer camp in one isolated geographic region of the United States. Each camper was only on site for 5 d. This study was conducted during a period when Alpha and Delta variants of SARS-CoV-2 were the most prevalent variants. The lower transmissibility of these variants than those of other variants, such as Omicron, poses a potential limitation to the generalizability of this study. Lastly, this study took place during a period with low community SARS-CoV-2 transmission rates (28 cases/100,000 7 d average in New York State over the 60 d study period).

## Conclusions

In this study, we described the implementation of a multilayered mitigation approach to infection control in a medically complex summer camp population. Future

research should focus on evaluating the effectiveness of such measures in broader geographic locations, times of higher community SARS-CoV-2 transmission rates, times of differing variants of concern, and populations with varying chronic medical conditions.

**Acknowledgments:** The authors thank Erik Reidel, MD for assisting in the development of study design.

**Author Contributions:** study concept and design (KW, SN, AA, CW); data acquisition (KW, SN, AA, CW); data analysis (KW, SN, AA, CW); drafting and critical revision of the manuscript (KW, SN, AA, CW); approval of final manuscript (KW, SN, AA, CW).

**Financial/Material Support:** None.

**Disclosures:** CW is the Medical Director of Double H Hole-in-the-Woods Ranch. SN is the Nursing Director of Double H Hole-in-the-Woods Ranch. None of the other authors have disclosures.

## References

1. Peacock-Villada E, Richardson BA, John-Stewart GC. Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. *Pediatrics*. 2011;127(2):e423–41.
2. Karimi M, Cox AD, White SV, Karlson CW. Fatigue, physical and functional mobility, and obesity in pediatric cancer survivors. *Cancer Nurs*. 2020;43(4):E239–45.
3. Centers for Disease Control and Prevention. CDC Museum COVID-19 timeline. Available at: <https://www.cdc.gov/museum/timeline/covid19.html#:~:text=January%2020%2C%202020%20CDC,18%20in%20Washington%20state>. Accessed August 3, 2022.
4. Bryson H, Mensah F, Price A, Gold L, Mudiyansele SB, Kenny B, et al. Clinical, financial and social impacts of COVID-19 and their associations with mental health for mothers and children experiencing adversity in Australia. *PLoS One*. 2021;16(9):e0257357.
5. Kaditis AG, Ohler A, Gileles-Hillel A, Choshen-Hillel S, Gozal D, Bruni O, et al. Effects of the COVID-19 lockdown on sleep duration in children and adolescents: a survey across different continents. *Pediatr Pulmonol*. 2021;56(7):2265–73.
6. Panda PK, Gupta J, Chowdhury SR, Kumar R, Meena AK, Madaan P, et al. Psychological and behavioral impact of lockdown and quarantine measures for COVID-19 pandemic on children, adolescents and caregivers: a systematic review and meta-analysis. *J Trop Pediatr*. 2021;67(1):fmaa122.
7. Stars I, Smane L, Pucuka Z, Roge I, Pavare J. Impact of pediatric COVID-19 on family health-related quality of life: a qualitative study from Latvia. *Glob Pediatr Health*. 2021;8:2333794X211012394.
8. Briery BG, Rabian B. Psychosocial changes associated with participation in a pediatric summer camp. *J Pediatr Psychol*. 1999;24(2):183–90.
9. McGregor S, McKenna J, Gately P, Hill AJ. Self-esteem outcomes over a summer camp for obese youth. *Pediatr Obes*. 2016;11(6):500–5.
10. Anarte MT, Carreira M, Leiva Gea A, Varela E, Mateo-Anarte M, Lopez Siguero JP, et al. Diabetes summer camp in children and adolescents with type 1 diabetes: effects on well-being and quality of life. *Endocrinol Diabetes Nutr (Engl Ed)*. 2020;67(5):326–32.
11. Darlington AE, Morgan JE, Wagland R, Soderger SC, Culliford D, Gamble A, et al. COVID-19 and children with cancer: parents' experiences, anxieties and support needs. *Pediatr Blood Cancer*. 2021;68(2):e28790.
12. Faith MA, Boone DM, Kalin JA, Healy AS, Rawlins J, Mayes S. Improvements in psychosocial outcomes following a summer camp for youth with bleeding disorders and their siblings. *J Pediatr Nurs*. 2021;61:144–50.
13. Faith MA, Mayes S, Pratt CD, Carter C. Improvements in hope and beliefs about illness following a summer camp for youth with chronic illnesses. *J Pediatr Nurs*. 2019;44:56–62.
14. Salazar G, Heyman MB. Benefits of attending a summer camp for children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2014;59(1):33–8.
15. Serlachius A, Badawy SM, Thabrew H. Psychosocial challenges and opportunities for youth with chronic health conditions during the COVID-19 Pandemic. *JMIR Pediatr Parent*. 2020;3(2):e23057.
16. Wimberly CE, Towry L, Caudill C, Johnston EE, Walsh KM. Impacts of COVID-19 on caregivers of childhood cancer survivors. *Pediatr Blood Cancer*. 2021;68(4):e28943.
17. Blaisdell LL, Cohn W, Pavell JR, Rubin DS, Vergales JE. Preventing and mitigating SARS-CoV-2 transmission—four overnight camps, Maine, June–August 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(35):1216–20.
18. D'Agostino EM, Armstrong SC, Humphreys L, Coffman S, Sinclair G, Permar SR, et al. Symptomatic SARS-CoV-2 transmission in youth and staff attending day camps. *Pediatrics*. 2021;147(4):e2020042416.
19. Kowalsky RH, Fine S, Eisenberg MA. Exclusion of SARS-CoV-2 from two Maine overnight camps July–August 2020. *Disaster Med Public Health Prep*. 2021;16(5):1–3.
20. Suh HH, Meehan J, Blaisdell L, Browne L. Non-pharmaceutical interventions and COVID-19 cases in US summer camps: results from an American Camp Association survey. *J Epidemiol Community Health*. 2022;76(4):327–34.
21. Szablewski CM, Chang KT, McDaniel CJ, Chu VT, Yousaf AR, Schwartz NG, et al. SARS-CoV-2 transmission dynamics in a sleep-away camp. *Pediatrics*. 2021;147(4):e2020046524.
22. Van Naarden Braun K, Drexler M, Rozenfeld RA, Deener-Agus E, Greenstein R, Agus M, et al. Multicomponent strategies to prevent SARS-CoV-2 transmission—nine overnight youth summer camps, United States, June–August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(40):1420–4.
23. Heavey L, Casey G, Kelly C, Kelly D, McDarby G. No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020. *Euro Surveill*. 2020;25(21):2000903.
24. Ehrhardt J, Ekinici A, Krehl H, Meincke M, Finci I, Klein J, et al. Transmission of SARS-CoV-2 in children aged 0 to 19 years in childcare facilities and schools after their reopening in May 2020, Baden-Württemberg, Germany. *Euro Surveill*. 2020;25(36):2001587.
25. Stein-Zamir C, Abramson N, Shoob H, Libal E, Bitan M, Cardash T, et al. A large COVID-19 outbreak in a high school 10 days after schools' reopening, Israel, May 2020. *Euro Surveill*. 2020;25(29):2001352.
26. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*. 2020;395(10242):197387.
27. Szablewski CM, Chang KT, Brown MM, Chu VT, Yousaf AR, Anyalechi N, et al. SARS-CoV-2 transmission and infection among attendees of an overnight camp - Georgia, June 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(31):1023–5.